Journal of Blood Medicine (May 2021)

Prevalence of Factor V Leiden G1691A and Prothrombin G20210A Gene Mutation Among Pregnant Women: Experience from a Multi-Center Study in Nigeria

  • John-Olabode SO,
  • Okunade KS,
  • James A,
  • Olorunfemi G,
  • Ajie OI,
  • Osuntoki AA,
  • Akanmu AS

Journal volume & issue
Vol. Volume 12
pp. 307 – 312

Abstract

Read online

Sarah O John-Olabode,1 Kehinde S Okunade,2 Ayorinde James,3 Gbenga Olorunfemi,4 Obiefuna I Ajie,5 Akinniyi A Osuntoki,6 Alani S Akanmu1 1Department of Hematology and Blood Transfusion, College of Medicine, University of Lagos, Lagos, Nigeria; 2Department of Obstetrics and Gynecology, College of Medicine, University of Lagos, Lagos, Nigeria; 3Department of Biochemistry and Nutrition, Nigerian Institute of Medical Research, Lagos, Nigeria; 4Division of Epidemiology and Biostatistics, School of Public Health, University of Witwatersrand, Johannesburg, South Africa; 5Department of Clinical Pathology, College of Medicine, University of Lagos, Lagos, Nigeria; 6Department of Biochemistry, College of Medicine, University of Lagos, Lagos, NigeriaCorrespondence: Sarah O John-OlabodeDepartment of Hematology and Blood Transfusion, College of Medicine, University of Lagos, Lagos, NigeriaTel +234 8096608152Email [email protected]: Inherited thrombophilia and venous thromboembolism (VTE) have been closely linked to adverse pregnancy outcomes such as preeclampsia/eclampsia contributing to increased maternal and perinatal morbidity and mortality. There is, however, little genetic data from Africa including Nigeria that explores the prevalence of common VTE genetic risk markers such as factor V Leiden mutation (FVL G1691A) and prothrombin gene mutation (F2 G20210A) among pregnant women in Nigeria.Purpose: To determine the prevalence and distribution of FVL G1691A and F2 G20210A in pregnant women in Lagos, Nigeria.Patients and Methods: This hospital-based cross-sectional pilot study was conducted among pregnant women between 1 July 2019 and 31 August 2020. The genotype of interest was determined through amplification by polymerase chain reaction using G1691A of FV and prothrombin A20210G specific primers. Descriptive data were presented using Stata version 15 (Stata Corp) statistical software.Results: Of the 400 recruited participants, 397 and 389 samples were successfully processed for FVL G1691A and F2 G20210A mutations, respectively. Three participants had FVL heterozygous mutation; thus, the prevalence of heterozygous mutation of FVL among the study participants was 0.76%, 95% CI: 0.002– 0.023%, n=3/397. There was no F2 G20210A mutation detected among the study participants.Conclusion: This study indicates that screening for factor V Leiden mutation and prothrombin gene mutation in pregnancy might not be of any clinical significance among Nigerian women. However, carrying out a genome-wide associated study is recommended to determine the true impact of these two common inherited thrombophilias in this population.Keywords: factor V Leiden G1691A, prothrombin G20210A gene mutation, factor 2, factor V, preeclampsia, venous thromboembolism

Keywords